Digestive System
Medications
Related eMedTV
Health Channels

Lubiprostone Dosage

For women with irritable bowel syndrome with constipation, the recommended lubiprostone dosage is 8 mcg twice daily. The recommended dose for treating chronic idiopathic constipation in men and women is lubiprostone 24 mcg twice daily. However, before prescribing a lubiprostone dose, your healthcare provider will consider several factors, such as other medical conditions you may have.

Lubiprostone Dosage: An Introduction

The dose of lubiprostone (Amitiza®) your healthcare provider recommends will vary, depending on a number of factors, including:
 
  • The medical condition being treated
  • Other medical conditions you may have.
     
As is always the case, do not adjust your dose unless your healthcare provider specifically instructs you to do so.
 

Dose of Lubiprostone for IBS

The recommended lubiprostone dose for treating irritable bowel syndrome (IBS) with constipation in women is lubiprostone 8 mcg twice daily with food and water. The medication is not approved for treating irritable bowel syndrome in men, as it has not yet been shown to be effective for this group.
 

Lubiprostone Dosage for Constipation

The recommended dose of lubiprostone for treating chronic idiopathic constipation (long-term constipation with no known cause) is lubiprostone 24 mcg twice daily with food and water. It is approved for both men and women for this use.
 

General Information on Your Lubiprostone Dosage

Some considerations for people taking lubiprostone include the following:
 
  • Lubiprostone comes in capsule form. It is usually taken by mouth twice daily with food and water.
     
  • Make sure to swallow the capsules whole. Do not chew or open them.
     
  • For the medication to work properly, it must be taken as prescribed. Lubiprostone will not continue to work if you stop taking it.
     
  • If you are unsure about anything related to your dosage or lubiprostone dosing in general, please talk with your doctor, nurse, or pharmacist.
     
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Other Articles in This eMedTV Presentation